Trial · NCT00208026
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
NCT00208026, Phase 1, Phase 2, Completed, Children's Hospital of Philadelphia; results first posted 2014-12-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome. Trials, record NCT00208026. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00208026
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
- NCT number
- NCT00208026
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- Children's Hospital of Philadelphia
- Conditions
- Netherton Syndrome
- Interventions
- Pimecrolimus 1% Cream
- First posted
- 2005-09-21
- Last updated
- 2019-08-14
- Results first posted
- 2014-12-12
- Limitations and caveats
- There were no early termination for any of the subjects.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Blood Pimecrolimus Levels | Each visit up to 18 months: Study Days 1, 7, 14, 28, 56, 84, 175, 360, and 520 | At each scheduled visit, blood concentration of pimecrolimus were obtained. This value reflects the amount of pimecrolimus in the blood. This is measured directly from the blood and provides an estimate of the degree of absorption of the treatment medication through the skin into the blood. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Blood Pimecrolimus Levels | Each visit up to 18 months: Study Days 1, 7, 14, 28, 56, 84, 175, 360, and 520 | ng/mL | NUMBER |
Source ClinicalTrials.gov
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Blood Pimecrolimus Levels | Patient 1 | Day 1 | 0 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 2 | Day 1 | 0 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 3 | Day 1 | 0.312 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 1 | Day 7 | 1.260 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 2 | Day 7 | 0.625 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 3 | Day 7 | 3.630 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 1 | Day 14 | 0.821 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 2 | Day 14 | 0.421 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 3 | Day 14 | 3.930 | ng/mL | |
| Blood Pimecrolimus Levels | Patient 1 | Day 28 | 0.592 | ng/mL |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Elidel (Pimecrolimus) 1% Cream | 3 | |
| Overall Study | COMPLETED | Elidel (Pimecrolimus) 1% Cream | 3 | |
| Overall Study | NOT COMPLETED | Elidel (Pimecrolimus) 1% Cream | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Elidel (Pimecrolimus) 1% Cream | ||
| Total, other adverse events | Elidel (Pimecrolimus) 1% Cream | 0 | 3 |
| Total, serious adverse events | Elidel (Pimecrolimus) 1% Cream | 0 | 3 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20083693 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00208026
GET https://conductscience.org/api/trials/v1/NCT00208026/results?page=2